| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0146-0005(99)80002-0 |
| P698 | PubMed publication ID | 10551789 |
| P2093 | author name string | Canick JA | |
| Kellner LH | |||
| P2860 | cites work | Physiological studies of human chorionic gonadotropin (hCG), alpha hCG, and beta hCG as measured by specific monoclonal immunoradiometric assays | Q35065657 |
| First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome | Q35822399 | ||
| Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. | Q38507170 | ||
| Biosynthesis of human chorionic gonadotropin | Q40124459 | ||
| Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy. | Q40400831 | ||
| Antenatal screening for Down's syndrome. | Q40909255 | ||
| First trimester serum screening for Down's syndrome | Q41034970 | ||
| Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome | Q41924002 | ||
| First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. | Q45291831 | ||
| Maternal serum screening for alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin between 11 and 15 weeks of pregnancy to detect fetal chromosome abnormalities | Q46300167 | ||
| First-trimester aneuploidy screening using serum human chorionic gonadotropin (hCG), free ahCG, and progesterone | Q46788795 | ||
| Maternal serum screening for Down syndrome in the first trimester: experience from Belarus | Q47328024 | ||
| Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. | Q52335333 | ||
| Maternal serum screening for Down syndrome in the United States: a 1995 survey. | Q53970056 | ||
| Pregnancy-associated plasma protein A: Circulating levels during normal pregnancy | Q54332016 | ||
| Abnormal maternal serum levels of human chorionic gonadotropin free subunits in trisomy 18 | Q61822481 | ||
| CA-125 as a maternal serum marker for Down's syndrome in the first and second trimesters | Q67536167 | ||
| Free beta-hCG as first-trimester marker for fetal trisomy | Q67537231 | ||
| First-trimester maternal serum human chorionic gonadotrophin as a marker for fetal chromosomal disorders. The Dutch Working Party on Prenatal Diagnosis | Q67547042 | ||
| First-trimester maternal serum biochemical indicators in Down syndrome | Q67663835 | ||
| Prenatal screening for trisomy 18 in the second trimester | Q67678252 | ||
| The Heterogeneity of Human Chorionic Gonadotropin (hCG). III. The Occurrence and Biological and Immunological Activities of Nicked hCG* | Q67697730 | ||
| First-trimester maternal serum alphafetoprotein and chorionic gonadotropin in aneuploid pregnancies | Q67706859 | ||
| Low maternal serum human chorionic gonadotrophin and unconjugated oestriol in a triploidy pregnancy | Q68029412 | ||
| Fetal chromosomal aneuploidies and maternal serum alpha-fetoprotein levels in first trimester | Q68966627 | ||
| Antigenic Constituents in Pregnancy Plasma which are Undetectable in Normal Non-Pregnant Female or Male Plasma | Q69373800 | ||
| First-trimester biochemical screening for Down syndrome | Q69924894 | ||
| Pregnancy associated plasma protein A as a marker for Down syndrome in the second trimester of pregnancy | Q70747437 | ||
| Screening for Down syndrome during the first and second trimesters: impact of risk estimation parameters | Q70787386 | ||
| Prenatal screening for Down's syndrome using inhibin-A as a serum marker | Q71124683 | ||
| Gene expression of human pregnancy-associated plasma protein-A in placenta from trisomic pregnancies | Q71267438 | ||
| Serum PAPP-A measurements in first-trimester screening for Down syndrome | Q71610146 | ||
| Maternal serum human chorionic gonadotrophin and pregnancy-associated plasma protein A, markers for fetal Down syndrome at 8-14 weeks | Q71639239 | ||
| Four-marker serum screening for Down's syndrome | Q71661694 | ||
| First trimester biochemical screening for trisomy 21: the role of free beta hCG, alpha fetoprotein and pregnancy associated plasma protein A | Q71670187 | ||
| Serum PAPP-A and free beta-hCG are first-trimester screening markers for Down syndrome | Q71677716 | ||
| Maternal serum screening for Down's syndrome in the first trimester of pregnancy | Q71707628 | ||
| Free beta hCG screening of hydropic and non-hydropic Turner syndrome pregnancies | Q71753829 | ||
| Low maternal serum levels of pregnancy associated plasma protein A (PAPP‐A) in the first trimester in association with abnormal fetal karyotype | Q72080653 | ||
| First‐trimester free beta (hCG) screening for Down syndrome | Q72099388 | ||
| Serum PAPP‐A levels are depressed in women with fetal Down syndrome in early pregnancy | Q72099390 | ||
| First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects | Q72714951 | ||
| Screening for Down syndrome during first trimester: a prospective study using free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A | Q73481833 | ||
| Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters | Q73543354 | ||
| Women's opinions and the implications of first- versus second-trimester screening for fetal Down's syndrome | Q73942507 | ||
| First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency | Q74223487 | ||
| Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery | Q74356921 | ||
| Screening of maternal serum for fetal Down's syndrome in the first trimester | Q74378735 | ||
| First-trimester biochemical markers for Down syndrome | Q74598371 | ||
| First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness | Q77327757 | ||
| Maternal serum screening for trisomy 18 in the first trimester of pregnancy | Q77482396 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 359-368 | |
| P577 | publication date | 1999-10-01 | |
| P1433 | published in | Seminars in Perinatology | Q15763431 |
| P1476 | title | First trimester screening for aneuploidy: serum biochemical markers | |
| P478 | volume | 23 |
| Q52057552 | First trimester PAPP-A in the detection of non-Down syndrome aneuploidy. |
| Q34333074 | First-trimester biochemical screening for Down syndrome |
| Q77358709 | Inclusion of early fetal deaths in a birth defects surveillance system |
| Q36335133 | Non-Invasive Screening Tools for Down's Syndrome: A Review |
| Q40717884 | Prenatal diagnosis and fetal therapy--what lies in future? |
| Q35171691 | Prenatal screening for Down syndrome: current and future methods |
| Q37611181 | The assessment of nuchal translucency and serum markers for down syndrome screening with ductus venosus Doppler measurements in the first trimester |
| Q36924916 | The associations of nuchal translucency and fetal abnormalities; significance and implications |
Search more.